PhuturdexDrug Pipeline Intelligence

Phuturdex › Diseases › Head and neck squamous cell carcinoma

Drugs in development · updated 30 October 2026

Head and neck squamous cell carcinoma: drugs in development

As of 30 October 2026 there are 427 active clinical trials (recruiting or ongoing, phases I–III) on 321 drugs for head and neck squamous cell carcinoma. 233 are experimental, that is not yet approved in the United States.

427Active trials
233Experimental drugs
31Experimental, in phase III

Summary updated every week · data as of 30 October 2026. In Phuturdex you get the full detail of every drug and an email when an alert is published on the ones you follow.

Sign in free →

Experimental drugs

Not yet approved by the US FDA for any indication.

DrugMost advanced phaseActive trialsReference trial
Becotatug VedotinMRG003III14NCT05751512
Ficerafusp alfaBCA101II–III6NCT06788990
NimotuzumabTheraloc®II–III6NCT07535567
SintilimabSinitilimab, SindilimabIII6NCT07827872
IvonescimabAK112III5NCT07264075
CamrelizumabCarrelizumab, CarilizumabIII4NCT07432087
FinotonlimabIII3NCT07509099
PetosemtamabMCLA-158III3NCT06496178
ZanzalintinibXL092II–III3NCT06082167
APG-157III2NCT07667296
BenmelstobartTQB2450II–III2NCT07535567
INBRX-106II–III2NCT06295731
JNJ-90301900III2NCT04892173
SYS6010III2NCT07758621
AK117III1NCT06601335
BemcentinibIII1NCT07445048
BNT113II–III1NCT04534205
ChemothearpyIII1NCT07509099
ChemotheraphyIII1NCT06992427
CispatinIII1NCT06258811
CRB-701III1NCT07768189
EnlituoII–III1NCT07791745
FiclatuzumabIII1NCT06064877
IAE0972II–III1NCT06719479
LigufalimabIII1NCT07264075
MonalizumabIII1NCT04590963
NedaplatinIII1NCT06102395
PRV111II–III1NCT05893888
PRV131II–III1NCT05893888
PRV211II–III1NCT05893888
TaxanesII–III1NCT06719479
PucotenlimabHX008II9NCT07844551
AdebrelimabSHR-1316, AdebelimabI–II7NCT07059221
SI-B001I–II5NCT05668858
Izalontamab brengitecanBL-B01D1, BMS-986507II3NCT06437522
Sacituzumab TirumotecanSKB264I–II3NCT04152499
SI-B003I–II3NCT05668858
BelrestotugII2NCT06062420
CadonilimabAK104, CandonilimabII2NCT06494995
CUE-101II2NCT07172256

Sorted by most advanced phase and number of active trials. Showing 40 of 233 drugs.

Approved drugs in new trials

Approved by the US FDA for at least one indication, not necessarily this disease, and now in active trials on it.

DrugMost advanced phaseActive trialsReference trial
PembrolizumabKEYTRUDA, MK-3475II–III112NCT06788990
CisplatinCis Platinum, CisplatineII–III79NCT05063552
CarboplatinCarboplatine, ParaplatinII–III56NCT05063552
CetuximabErbituxII–III39NCT05063552
PaclitaxelTaxol, PaxlitaxelIII33NCT05721755
NivolumabOpdivo, ONO-4538II–III26NCT03952585
DocetaxelTaxotere, Beizray®II–III25NCT05063552
TislelizumabTisleizumab, TiselizumabIII19NCT06258811
ToripalimabJS001, TeripalimabII–III17NCT05125055
Fluorouracil5-Fluorouracil, AdrucilII–III16NCT05125055
Nab-paclitaxelAbraxane, Nab-placlitaxelIII15NCT07827872
GemcitabineGemcitabin, GemzarII–III7NCT06719479
AtezolizumabTecentriq, MPDL3280AII–III6NCT05063552
AvelumabBavencio®III6NCT02999087
Bevacizumabavastin, MVASIII–III6NCT05063552

Sorted by most advanced phase and number of active trials. Showing 15 of 88 drugs.

All 321 drugs, with the details

In Phuturdex every drug has all its trials, sponsors and countries, FDA and EMA approvals, orphan designations and safety alerts. Free until 31 March 2027.

Open in Phuturdex →

Broader categories

Source: Phuturdex analysis of ClinicalTrials.gov data (U.S. National Library of Medicine), updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III, with at least one identified drug; phase and sites refer to the trials on this disease. Disease name: Wikidata; NLM MeSH term: D000077195 “Squamous Cell Carcinoma of Head and Neck”.

ItalianoFrançaisDeutsch